Defactinib registry update: MATCH-Subprotocol U in cancers with NF2 genetic changes — LiveFuture News
Open on LiveFuture.ai →

Defactinib registry update: MATCH-Subprotocol U in cancers with NF2 genetic changes

ClinicalTrials.gov lists a phase 2 study of defactinib for cancers with NF2 genetic changes as active not recruiting, with objective response rate as the main outcome and results posted.

A phase 2 ClinicalTrials.gov listing for Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) now shows an ACTIVE_NOT_RECRUITING status. The record is published 2026-11-09T00:00:00+00:00, and it also says has_results: true, which means the study is no longer in the setup stage and has posted results for readers to review.

For people following targeted cancer research, the key point is simple: this registry entry ties defactinib to cancers with NF2 genetic changes and identifies Objective Response Rate (ORR) as the primary outcome. That outcome tracks the percentage of patients whose tumors had a complete or partial response among analyzable patients, using standard response criteria named in the study details.

"This record describes a study and its registry status; study outcomes require posted results." source: ctgov_v2

What the study measures

The outcome window is also spelled out clearly. Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration. That kind of schedule shows the study was built to follow response over time rather than after a single visit.

The intervention listed is Defactinib Hydrochloride, and the arm group is labeled Treatment (defactinib). The sponsor is National Cancer Institute (NCI), which anchors the study inside a public cancer research setting rather than a commercial product announcement.

"ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients." source: ctgov_v2

Where it fits in the wider cancer update

The registry observation sits inside the Cancer Breakthroughs special event, alongside other cancer studies that are currently recruiting, not yet recruiting, or active not recruiting. That broader context suggests a steady stream of oncology registry updates, but each listing still stands on its own status and design.

Related entries in the same event include studies of germline RUNX1 associated blood cancers, CRLF2-R/TSLPR-overexpressing B-ALL, myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms, and recurrent glioma. They share a cancer-research theme, but they do not change the specific details of the defactinib study.

"Registry observation: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) (PHASE2, ACTIVE_NOT_RECRUITING)" source: ctgov_v2